亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Ziresovir for Treatment of RSV Bronchiolitis in Young Infants

出处
期刊:Aap Grand Rounds [American Academy of Pediatrics]
卷期号:54 (2): 15-15
标识
DOI:10.1542/gr.54-2-15
摘要

Source: Zhang H, Zhao W, Zhang X, et al. Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up. Lancet Child Adolesc Health. 2025;9(5):325-336; doi: 10.1016/S2352-4642(25)00067-7.Investigators from multiple institutions conducted a randomized controlled trial assessing the efficacy and safety of ziresovir in children 1–24 months old with confirmed respiratory syncytial virus (RSV) infection who were hospitalized at 1 of 28 hospitals in China. The current study includes the results of a preplanned analysis of infants <6 months old who were enrolled in the trial. Eligibility criteria included a positive PCR for RSV and a Wang bronchiolitis clinical score (WBCS) of 35 at the time of administration of the first dose of study drug. The WBCS assesses respiratory rate, wheezing, retractions, and general condition using a 0–3 score for each component; higher scores are indicative of more severe disease. Study participants were randomized to receive ziresovir or placebo orally twice daily for 5 days. The study was conducted in 2 phases, with patients included in phase 1 assessed for safety and those in phase 2 evaluated for safety and efficacy. For those in phase 2, the primary outcome was change in WBCS from baseline to day 3. Secondary efficacy outcomes included change in viral load from baseline to day 5 and length of stay (LOS) following the first dose of study drug. The parents of infants in phase 2 were contacted up to 2 years after enrollment to collect data on subsequent episodes of wheezing in their children. Outcomes in participants randomized to ziresovir or placebo were compared with a variety of statistical tests. Drug-related, treatment-emergent, adverse events among patients in the 2 treatment groups also were compared.Data on 188 infants (125 in the ziresovir group and 63 randomized to placebo) were included in the safety analyses; 150 patients (100 randomized to ziresovir and 50 to placebo) were enrolled in the efficacy trial. The mean change in WBCS from baseline to day 3 was -3.5 points for children receiving ziresovir and -2.2 points for those in the placebo group (P = 0.0004). The reduction in viral load from baseline to day 5 was significantly greater in patients randomized to ziresovir than in placebo recipients (P = 0.024). There was no significant difference between groups for LOS. Drug-related, treatment-emergent, adverse events were reported in 22 (18%) children randomized to ziresovir and 7 (11%) of those randomized to placebo. The most common adverse event in ziresovir recipients was diarrhea, reported in 6 patients. Follow-up data were collected on 78 children who received ziresovir and 38 who were randomized to placebo. The annualized rates of wheeze in the 2 groups were 0.18 and 0.65 episodes, respectively (P = 0.005).The authors conclude that ziresovir had a positive clinical benefit, both in the immediate and long term, among infants <6 months old hospitalized for RSV.Dr Chang has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.RSV infections are a leading cause of hospitalizations for young children, and infants <6 months of age are at higher risk for severe illness.1 In addition, previous investigators have found an association between infant RSV infections and future asthma development. (See AAP Grand Rounds. 2023;50[3]:27.)2 The authors of the current industry-sponsored study had previously reported that ziresovir, an orally administered RSV fusion protein inhibitor, was well tolerated and effectively reduced clinical signs and symptoms in hospitalized children aged 1–24 months with RSV. (See AAP Grand Rounds. 2025;53[1]:3.)3 The current study further characterized the efficacy of ziresovir for hospitalized children in the 1–6-month age group in the immediate period and during a longer-term follow-up of 2 years.The rigorous study design and methodology are notable strengths of this study, but study populations were small. While the WBCS was statistically lower in the ziresovir group compared to the placebo group, it is unclear whether the difference of 1.3 points between groups translates to clinically meaningful benefit. Similarly, while infants in the ziresovir group had lower rates of wheeze, wheeze was parent-reported and of unclear clinical significance, and a 2-year follow-up is insufficient to assess the incidence of asthma diagnoses. Though it remains to be seen whether ziresovir will be a clinically- and cost-effective treatment for RSV infections, this study presents an exciting therapeutic development, particularly for vulnerable, high-risk young infants.Oral ziresovir is a potentially promising new treatment for RSV infections in hospitalized young infants.Therapy of RSV infections is currently limited to aerosolized ribavirin for life-threatening infections in immunocompromised patients. The holy grail remains a safe and efficacious pediatric vaccine—now only available for pregnant women.4 No RSV vaccine is available for direct administration to infants. Thus, the results of this trial, especially if repeated in larger, ethnically diverse populations and in outpatient settings, suggest an oral antiviral—ziresovir—may be at least an interim chemotherapeutic option.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
满意的平凡完成签到,获得积分10
1秒前
伶俐的秀发完成签到,获得积分10
2秒前
ChenYQ完成签到,获得积分10
28秒前
苹果完成签到 ,获得积分10
35秒前
殷勤的半凡完成签到,获得积分10
56秒前
耍酷的手套完成签到,获得积分10
1分钟前
1分钟前
1分钟前
充电宝的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
orixero的应助被爱学习的doge采纳,获得10
1分钟前
隐形曼青的应助被爱学习的doge采纳,获得10
1分钟前
在水一方的应助被爱学习的doge采纳,获得10
1分钟前
大模型的应助被爱学习的doge采纳,获得10
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
香蕉觅云的应助被爱学习的doge采纳,获得10
1分钟前
CodeCraft的应助被爱学习的doge采纳,获得10
1分钟前
SciGPT的应助被爱学习的doge采纳,获得10
1分钟前
隐形曼青的应助被爱学习的doge采纳,获得10
1分钟前
小二郎的应助被爱学习的doge采纳,获得10
1分钟前
852的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
田様的应助被爱学习的doge采纳,获得10
1分钟前
脑洞疼的应助被爱学习的doge采纳,获得10
1分钟前
bkagyin的应助被爱学习的doge采纳,获得10
1分钟前
顺利水桃完成签到,获得积分10
1分钟前
1分钟前
乐乐的应助被mengdewen采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918